Andrea Stevens

Senior Director, Precision Medicine Access Johnson & Johnson Innovative Medicine

Thursday 8th October 2026

Panel Discussion: Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers

9:00 am

How can multi‑company collaboration accelerate global access to comprehensive genomic profiling, particularly in regions where testing infrastructure and reimbursement remain limited?
What operational barriers most constrain CGP adoption, and what tools can help standardize processes across health systems?
How can harmonized testing pathways, shared training resources, and coordinated industry engagement reduce variation in CGP turnaround times and improve diagnostic quality globally?

Thursday 8th October 2026

Expanding Access to Precision Cancer Care with the Precision Cancer Consortium CGP Implementation Guide

8:10 am

Advancing Access to Precision Oncology: The Precision Cancer Consortium developed The Pathway to Precision Cancer Care, a strategic and operational guide to help health systems embed comprehensive genomic profiling (CGP) into routine cancer care and expand patient access globally
The Impact of Limited CGP Capacity: Without coordinated action, patients miss opportunities for accurate diagnosis, targeted therapies, and clinical trials; costs rise due to inefficiencies; results may be delayed or misinterpreted; and patients and families lack information for shared decision-making
Clinical & Economic Value at Risk: Limited access to CGP constrains patient outcomes and prevents health systems from realizing the wider economic value that precision oncology can deliver beyond healthcare
Practical, Adaptable Solutions: The freely available, interactive guide provides actionable steps, tools, and real world examples to help health systems initiate, scale, and strengthen CGP programs. This session highlights how it is being used to improve access to optimal treatments